Agentix Corp.
AGTX · OTCMCIK 1603345fmd_0G31B02H5928FETF16JA0XVC4GManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Mar 01, 2013 to Sep 30, 2026, 56 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | – | – | 0 | 0 | – | – | – |
| Cost of revenue | 0 | 0 | – | – | – | 0 | 0 | – | – | – |
| Net interest income | – | 0 | 0 | – | – | – | – | – | – | – |
| Gross profit | 0 | 0 | – | – | – | 0 | 0 | – | – | – |
| Research and development | 0 | – | – | – | – | 0 | 1 | 0 | 0 | 0 |
| Total operating expenses | 0 | 0 | 0 | 0 | – | 3 | 1 | 1 | 1 | 0 |
| Operating income | (0) | (0) | (0) | (0) | – | (3) | (1) | (1) | (1) | (0) |
| Interest expense | – | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 0 | 43 | – | (0) | – | 0 | 0 | (0) | – |
| Income before taxes | (0) | (0) | (43) | (0) | (1) | – | (1) | (1) | (1) | (0) |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (0) | – | – | – | (1) | – | (1) | (1) | (1) | (0) |
| Net income | (0) | (0) | (43) | (0) | – | (3) | (1) | (1) | (1) | (0) |